US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

20.00

-0.0500-0.25%

Volume:89.78K

Turnover:1.80M

Market Cap:576.90M

PE:32.26

High:20.27

Open:20.27

Low:19.77

Close:20.05

Loading ...

Overview Company News Filings

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

Kymera Provides Pipeline Objectives for 2025, Stock Gains

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)

BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023

Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023

THOMSON REUTERS

Press Release: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Castle Biosciences drops as regional Medicare contractor won’t cover test

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSTL/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":20,"timestamp":1746114025256,"preClose":20.05,"halted":0,"volume":89783,"delay":0,"floatShares":26497706,"shares":28844937,"eps":0.62,"marketStatus":"Trading","change":-0.05,"latestTime":"05-01 11:40:32 EDT","open":20.27,"high":20.27,"low":19.765,"amount":1799426.217284,"amplitude":0.025187,"askPrice":20.02,"askSize":242,"bidPrice":19.98,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.62,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":20.05,"preHourTrading":{"tag":"盘前","latestPrice":20.22,"preClose":20.05,"latestTime":"08:49 EDT","volume":716,"amount":14695.119560000001,"timestamp":1746103747167},"postHourTrading":{"tag":"盘后","latestPrice":20.05,"preClose":20.05,"latestTime":"19:35 EDT","volume":13819,"amount":277071.19,"timestamp":1746056130891},"volumeRatio":0.645201,"impliedVol":0.4466,"impliedVolPercentile":0.148},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26497706,"roa":"1.10%","roe":"4.31%","lyrEps":0.656862,"volumeRatio":0.645201,"shares":28844937,"dividePrice":0,"high":20.27,"amplitude":0.025187,"preClose":20.05,"low":19.765,"week52Low":16.965,"pbRate":"1.27","psRate":"1.74","week52High":35.84,"institutionHeld":0,"latestPrice":20,"committee":-0.959514,"eps":0.62,"divideRate":0,"volume":89783,"delay":0,"ttmEps":0.62,"open":20.27,"prevYearClose":26.65,"prevWeekClose":20.63,"prevMonthClose":20.05,"prevQuarterClose":20.02,"fiveDayClose":20.93,"twentyDayClose":20.19,"sixtyDayClose":28.15,"earningDate":1746374400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2504949490","title":"MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2504949490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504949490?lang=en_us&edition=fundamental","pubTime":"2025-01-17 01:09","pubTimestamp":1737047340,"startTime":"0","endTime":"0","summary":"Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli , which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.MIRM acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.In the past year, shares of Mirum have rallied 73.3% against the industry’s decline of 16%.Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis  patients is currently under review in the United States. A decisi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirm-shares-rise-12-week-170900763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","CSTL","CTMX","BK4139","MIRM","VYGR"],"gpt_icon":0},{"id":"2504433569","title":"InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2504433569","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504433569?lang=en_us&edition=fundamental","pubTime":"2025-01-16 23:49","pubTimestamp":1737042540,"startTime":"0","endTime":"0","summary":"InflaRx N.V.IFRX shares gained 7.7% on Wednesday following the European Commission's  approval of marketing authorization, under exceptional circumstances, for Gohibic  to treat adult patients with acute respiratory distress syndrome  caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation.The EC’s approval makes Gohibic the first and only approved treatment for SARS-CoV-2-induced ARDS in the EU. We remind the investors that in November 2024, the advisory committee to the European Medicines Agency had adopted a positive opinion recommending approval of the drug for the above indication, under exceptional circumstances. Gohibic is a first-in-class anti-C5a monoclonal antibody.More on the EC Nod for IFRX’s COVID-19-Induced ARDS Drug. The EU approval ofInflaRx’s Gohibic for the ADRS indication is ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inflarx-stock-rises-8-conditional-154900009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2552382132.HKD","SG9999001440.SGD","CTMX","IE00BBT3K403.USD","LU0094547139.USD","LU2242652126.USD","EC","LU1868836591.USD","SG9999014575.USD","BK4504","LU0320765646.SGD","LU0689626769.HKD","LU1929549753.HKD","BK4568","IE00B7SZLL34.SGD","SG9999002232.USD","LU2552382215.SGD","IE00BLSP4239.USD","BK4196","IE00BWXC8680.SGD","BK4201","PG","LU0061475181.USD","LU0124676726.USD","BK4551","ARDS","LU1430594728.SGD","CSTL","SG9999015358.SGD","BK4533","LU0098860793.USD","BK4018","LU1868837300.USD","SG9999002224.SGD","LU2242646821.SGD","BNTX","BK4139","BMRN","IE000M9KFDE8.USD","LU1868837136.USD","SG9999014559.SGD","IFRX","IE00BLSP4452.SGD","LU0640476718.USD","LU0868494617.USD","BK4548","LU1066051498.USD","LU1066053197.SGD","LU1280957306.USD","BK4581"],"gpt_icon":0},{"id":"2503749996","title":"Kymera Provides Pipeline Objectives for 2025, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2503749996","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503749996?lang=en_us&edition=fundamental","pubTime":"2025-01-16 02:30","pubTimestamp":1736965800,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs.Shares of KYMR have surged 47.2% in a year against the industry’s decline of 16%.Kymera is developing KT-621, an investigational, first-in-class, once-daily oral degrader of STAT6. The candidate has demonstrated dupilumab-like activity and very good safety data in preclinical models.Kymera expects to complete this phase I study and report data in the second quarter of 2025. It will also advance the candidate in a phase lb study in AD patients in the second quarter of 2025 and report data in the fourth quarter of the year.Kymera is also evaluating KT-295, an investigational, first-in-class, once-daily oral degrader of TYK2, a member of the Janus kinase  family required for Type I IFN, IL-12 and IL-23 signaling.The company expects to file an investigational new drug application for the candidate and initiate dosing in the phase I healthy volunteer c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-provides-pipeline-objectives-2025-183000231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","SNY","KYMR","BMRN","IE00B19Z3581.USD","IE00BFXG1179.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4566","IE0002270589.USD","CSTL","BK4588","BK4196","BK4139"],"gpt_icon":0},{"id":"2503273621","title":"TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2503273621","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503273621?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:10","pubTimestamp":1736950200,"startTime":"0","endTime":"0","summary":"TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi , which exceeded the company’s initial expectations.TGTX also provided its guidance for 2025 and outlined some expected milestones related to Briumvi label expansion studies and other pipeline candidates for 2025.Briumvi is approved for the treatment of certain adult patients with relapsing forms of multiple sclerosis .In the past year, shares of TG Therapeutics have rallied 96.2% against the industry’s decline of 14.8%.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 33%.In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.5%.CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tgtx-announces-2024-preliminary-results-141000241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089283258.USD","BK4504","LU1668664300.SGD","LU1162221912.USD","LU0106261372.USD","TGTX","VYGR","LU1363072403.SGD","BK4581","BK4139","LU1989772840.SGD","LU2271345857.HKD","BK4585","BK4588","LU1732799900.SGD","LU0267386448.USD","LU2111349929.HKD","LU1720051108.HKD","LU1074936037.SGD","LU2347655156.SGD","IE00BZ1G4Q59.USD","BK4534","LU0971096721.USD","LU0006306889.USD","LU1720051017.SGD","LU0158827948.USD","LU1989772923.USD","LU2023251221.USD","LU2089284900.SGD","IE00BKVL7J92.USD","CSTL","CTMX","LU0106831901.USD","LU0314104364.USD","BK4196","BK4127","BK4516","LU0912757837.SGD","LU0225283273.USD","LU0320765646.SGD","LU0795875169.SGD","LU1548497426.USD","LU2357305700.SGD","LU2028103732.USD","LU0158827781.USD","LU0098860793.USD","LU0795875086.SGD","LU1732800096.USD"],"gpt_icon":0},{"id":"2503056435","title":"Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2503056435","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503056435?lang=en_us&edition=fundamental","pubTime":"2025-01-14 23:14","pubTimestamp":1736867640,"startTime":"0","endTime":"0","summary":"Shares of Blueprint MedicinesBPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise.Blueprint’s commercial portfolio only comprises its lead drug Ayvakit , an inhibitor of KIT and PDGFRA proteins,which was initially approved in the United States and the EU to treat gastrointestinal stromal tumors in 2020. Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis .The company anticipates reporting its fourth-quarter and full-year 2024 results in February 2025. In October 2024, Blueprint projected Ayvakit product revenues in the range of $475-$480 million for the year, marking growth of more than 130% compared with 2023. The growth trajectory of Ayvakit sales is expected to continue rising in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blueprint-stock-soars-18-encouraging-151400664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","SM","BK4213","CTMX","BPMC","HALO","BK4505","CSTL","BK4139","BK4196"],"gpt_icon":0},{"id":"2503555448","title":"Biogen Offers to Buy Remaining Stake in Sage Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503555448","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503555448?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:00","pubTimestamp":1736798400,"startTime":"0","endTime":"0","summary":"Sage Therapeutics  said Biogen  has made an unsolicited offer to acquire the rest of SAGE shares.Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will review the offer.Sage Therapeutics SAGE announced that its partner Biogen BIIB has made an unsolicited, non-binding proposal offer to acquire the SAGE shares that it does not already own for $7.22per share. The offer price represents a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Friday.At present, Biogen owns a 10.2% stake in SAGE, per a SEC filing by the company. Sage Therapeutics’ board will review and evaluate the offer and will come to a final decision.SAGE’s stock was up 46% in after-hours trading on Friday in response to the news while Biogen was down slightly.Biogen’s shares have declined 40%, while Sage Therapeutics’ stock has been down 79.1% in the past year, compared with a decrease of 15.9% for the industry.In September, Biogen terminated its rights under the collaboration and lic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-offers-buy-remaining-stake-200000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBYI","PPD","BK4590","LU0234570918.USD","BK4581","BK4139","BK4585","LU0109394709.USD","LU0320765992.SGD","BK4588","SAGE","IE00B19Z9Z06.USD","MCI","BK4533","IE00B894F039.SGD","BK4561","CSTL","BK4144","BK4196","BK4121","IE00B19Z9P08.USD","BIIB","LU0889565916.HKD","ET","ABVC","BK4530","BK4532"],"gpt_icon":0},{"id":"2503353959","title":"PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2503353959","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503353959?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:43","pubTimestamp":1736786580,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company unveiled a five-year growth strategy aimed at accelerating its transformation into an innovative biopharmaceutical company and establishing itself as a leader in musculoskeletal pain and related areas. This has also likely contributed to the stock price rally.Pacira did not recognize any other revenues, comprising sales of bupivacaine liposome injectable suspension and royalties, in the fourth quarter of 2024. In the year-ago period, the company recognized $2.6 million in other revenues.Pacira has outlined its ambitious \"5x30\" strategy, a growth-oriented plan designed to drive innovation and value creation by 2030. Central to this vision is the goal of treating more than three million patients annually while achieving a double-digit compounded annual growth rate in product revenues. The c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-rises-11-upbeat-164300518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","CSTL","CTMX","HALO"],"gpt_icon":0},{"id":"2503534916","title":"ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz","url":"https://stock-news.laohu8.com/highlight/detail?id=2503534916","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503534916?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:40","pubTimestamp":1736786400,"startTime":"0","endTime":"0","summary":"Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire. The litigation is currently pending in the U.S. District Court in New Jersey.Caplyta is approved in the United States for the treatment of schizophrenia in adults. Later, its indication was expanded to treat bipolar depression in adults. Intra-Cellular’s Caplyta is currently the only approved treatment, both as monotherapy and as adjunctive therapy with lithium or valproate, for depressive episodes associated with bipolar depression in adults.In 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itci-stock-rises-15-settling-164000815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SDZNY","BK4007","BK4139","LU0053671581.USD","LU0012050646.USD","CTMX","LU0889565916.HKD","ITCI","BK4196","LU0109394709.USD","LU0320765992.SGD","LU0106261612.USD","CSTL"],"gpt_icon":0},{"id":"2503391055","title":"Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503391055","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503391055?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:31","pubTimestamp":1736785860,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics FOLD announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold , which is approved for treating Fabry disease and Pombiliti + Opfolda.The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.In the past year, shares of Amicus have plunged 31.6% compared with the industry’s decline of 16%.For full-year 2025, management expects total revenues to grow in the range of 17%-24% on a constant exchange rate .Revenues from Galafold are expected to grow in the range of 10%-15% at CER in 2025.Both Fabry disease and Pompe disease are rare diseases. Amicus is currently advancing ongoing studies to broaden labels in Fabry and Pompe diseases.Amicus expects to achieve positive GAAP net income in the second half of 2025. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amicus-posts-preliminary-2024-results-163100240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","LU2065171402.SGD","BK4139","TEVA","BK4596","BK4584","BK4566","CTMX","BK4557","BK4559","BK4585","CSTL","BK4588","LU2065170008.USD","LU2065171311.SGD","BK4196","BK4007","FOLD"],"gpt_icon":0},{"id":"2503853591","title":"Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503853591","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503853591?lang=en_us&edition=fundamental","pubTime":"2025-01-13 23:13","pubTimestamp":1736781180,"startTime":"0","endTime":"0","summary":"Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-nave, high-risk, non-muscle invasive bladder cancer , including patients with carcinoma in-situ .Results from the study showed that treatment with subcutaneously administered sasanlimab combined with standard-of-care BCG vaccine resulted in a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival  compared to BCG alone.Though Pfizer did not share any numbers supporting this data, management mentioned that the study results mark a significant milestone in a therapeutic area that has seen little progress over the past 30 years. It also mentioned that the drug’s safety profile was consistent with other PD-1 inhibitors.If approved, Pfizer claims that sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong EFS in the BCG-nave high-risk NMIBC patien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-meets-goal-non-muscle-151300396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","LU0106261372.USD","LU0122379950.USD","LU2106854487.HKD","IE00BJJMRZ35.SGD","BK4585","LU1066051225.USD","BK4539","LU0070302665.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU1093756168.USD","LU1989771016.USD","LU0985320562.USD","LU0265550946.USD","LU0211331839.USD","LU1037948541.HKD","LU0456855351.SGD","LU0965508806.USD","LU1061106388.HKD","LU1162221912.USD","LU1974910355.USD","LU2023250504.SGD","LU1983299246.USD","BK4139","IE00B19Z3581.USD","LU1116320901.HKD","LU1571399168.USD","LU1934455863.HKD","SG9999001440.SGD","LU0266013472.USD","ERAS","SG9999015341.SGD","LU1989772840.SGD","BK4534","LU1941712348.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","CSTL","LU0058720904.USD","LU1430594728.SGD","LU1894683348.USD","LU0306807586.USD","PFE","MRK","LU0238689110.USD","LU0321505439.SGD","SG9999002224.SGD","LU2112291526.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2503637180","title":"BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503637180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503637180?lang=en_us&edition=fundamental","pubTime":"2025-01-13 18:25","pubTimestamp":1736763952,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro maintained a Buy rating on Castle Biosciences (CSTL – Research Report) today and set a price target of $40.00. The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-castle-biosciences-cstl-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-castle-biosciences-cstl-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSTL"],"gpt_icon":0},{"id":"2503390959","title":"BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390959?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:01","pubTimestamp":1736722911,"startTime":"0","endTime":"0","summary":"BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023Jan 12 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES INC - 2024 REVENUE EXPECT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL"],"gpt_icon":0},{"id":"2503390953","title":"Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390953?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:00","pubTimestamp":1736722834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2503390656","title":"Press Release: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390656?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:00","pubTimestamp":1736722800,"startTime":"0","endTime":"0","summary":"2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023. Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023. Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million. Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024.\"Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initiatives and the dedication of our team,\" said Derek Maetzold, president and chief executive officer of Castle Biosciences. \"As a result, we expect to meet or exceed the top end of our full-year 2024 revenue guidance of $320-330 million. This achievement reflects our commitment to delivering value to our stockholders whil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4022","CSTL","BK4196"],"gpt_icon":0},{"id":"2502816855","title":"Castle Biosciences drops as regional Medicare contractor won’t cover test","url":"https://stock-news.laohu8.com/highlight/detail?id=2502816855","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502816855?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:50","pubTimestamp":1736535032,"startTime":"0","endTime":"0","summary":"Castle Biosciences (CSTL) shares are lower in Friday trading after Novitas, a regional Medicare contractor, finalized its decision to not cover one...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/castle-biosciences-drops-as-regional-medicare-contractor-wont-cover-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/castle-biosciences-drops-as-regional-medicare-contractor-wont-cover-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2502081025","title":"FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2502081025","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502081025?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:42","pubTimestamp":1736534520,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental new drug application  for cabozantinib.In November 2024, the FDA notified the company that the sNDA for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET  would be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The FDA has now notified the company that its sNDA will no longer be the subject of discussion at the ODAC meeting. The sNDA is under FDA review and has a target action date of April 3, 2025.Exelixis’ shares have gained 53.2% in the past six months against the industry’s decline of 10.1%.In August 2023, the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board unanimously recommended that enrollment in the CABINET trial be stopped and randomized patients be unblinded to therapy with the allowance for crossover from placebo to cabozantini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-updates-exel-previously-scheduled-184200304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948897.HKD","LU0006306889.USD","LU0265550946.USD","BK4585","EXEL","LU1061106388.HKD","SG9999015341.SGD","DTC","IE00B2B36J28.USD","LU1571399168.USD","SG9999002232.USD","BK4211","BK4516","LU1023059063.AUD","LU1066051811.HKD","BK4532","LU1093756168.USD","LU1989772840.SGD","LU2089984988.USD","LU0985320562.USD","IE000M9KFDE8.USD","IE0002141913.USD","LU0965509010.AUD","BK4533","LU0058720904.USD","LU2112291526.USD","LU0208291251.USD","LU2361045086.USD","LU0320765489.SGD","MRK","RCC","LU2106854487.HKD","LU1057294990.SGD","LU1934455277.USD","IE00BJJMRZ35.SGD","SG9999002224.SGD","LU1291159041.SGD","SG9999013999.USD","PFS","IE0009355771.USD","LU0211331839.USD","IE00B1BXHZ80.USD","LU1941712264.USD","IMCR","LU1699723380.USD","SG9999015358.SGD","BK4139","CSTL","SGXZ57979304.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2502520890","title":"SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2502520890","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502520890?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:16","pubTimestamp":1736522160,"startTime":"0","endTime":"0","summary":"Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes  study of its experimental cell therapy, UP421.Notably, in the investigator-sponsored, first-in-human study, UP421 was transplanted into a patient with T1D without the use of any immunosuppression. UP421, an allogeneic primary islet cell therapy, is being developed in partnership with Uppsala University Hospital, utilizing Sana’s proprietary hypoimmune  technology.The study results were evaluated four weeks after intramuscular cell transplantation, which confirmed the survival and functionality of pancreatic beta cells in the first treated T1D patient. The results were supported by the presence of circulating C-peptide, a biomarker indicating insulin production by the transplanted beta cells.C-peptide levels further increased during a mixed meal tolerance test, demonstrating insulin secretion in response to a meal. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sana-stock-surges-152-week-151600351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","CTMX","CSTL","BK4139","SANA","HALO","LU0053671581.USD"],"gpt_icon":1},{"id":"2502468898","title":"FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2502468898","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502468898?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:24","pubTimestamp":1736515440,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor  blocker, in generalized myasthenia gravis  indication.The filing has been granted priority review by the FDA, bringing down the review period by four months. We expect a final decision in the third quarter of 2025.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care achieved sustained disease controlover 24 weeks compared with those who received placebo plus SOC. A similar regulatory filing for the drug is under review by the EMA, also supported by data from this study.Per J&J, the above results make Vivacity-MG3 the first and only study to achieve sustained disease control in gMG patients wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-j-js-filing-132400420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","IE0009355771.USD","LU0122379950.USD","LU1032955483.USD","LU0109394709.USD","BK4550","LU0345770993.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4213","LU1066051498.USD","LU0792757196.USD","IE00BVYPNV92.GBP","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0098860793.USD","CTMX","LU0058720904.USD","LU1032466523.USD","JNJ","LU1221951046.USD","LU1261432733.SGD","LU1280957306.USD","LU0320765992.SGD","LU1732800096.USD","SG9999001440.SGD","IE0002270589.USD","LU1935042991.SGD","LU0234570918.USD","BK4505","LU1244550577.SGD","BK4533","LU0345769128.USD","ARGX","LU0466842654.USD","LU0345770308.USD","LU0889565916.HKD","IE00B1BXHZ80.USD","LU0912757837.SGD","SOC","BK4139","LU1066051225.USD","LU0320765646.SGD","LU1066051811.HKD","IE0034235303.USD","CSTL","LU1894683264.USD","LU1162221912.USD","LU1674673691.USD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2502636025","title":"VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2502636025","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502636025?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:42","pubTimestamp":1736440920,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.While VIR-5818 is designed to target a variety of HER2-expressing solid tumors, VIR-5500 is designed to target PSMA in metastatic castration-resistant prostate cancer .Initial data from the phase I study demonstrated compelling early clinical response signals for both T-cell engagers , VIR-5818 and VIR-5500, in heavily pretreated patients with various types of solid tumors.Shares of Vir Biotechnology jumped 58.2% on Jan. 8 following the announcement of the news.In the past year, shares of VIR have rallied 21.1% against the industry’s decline of 14.3%.Per the company, VIR-5818 and VIR-5500 leverage the PRO-XTEN masking technology with different TCEs targeting HER2 and PSMA, respectively. The technology is designed to allow the selective activation of TCEs in the tumor microenvironment,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-stock-early-safety-efficacy-164200842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","BK4217","CRC","BK4139","CSTL","PBYI","BK4196","LU0456854461.SGD","BK4084","BK4535","BK4588","CTMX","BK4213","PSA","VIR","BK4568","BK4585","LU0266512127.USD"],"gpt_icon":0},{"id":"2502041401","title":"CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2502041401","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502041401?lang=en_us&edition=fundamental","pubTime":"2025-01-09 22:53","pubTimestamp":1736434380,"startTime":"0","endTime":"0","summary":"Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor,SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA regarding the Firdapse  patent litigation.The settlement agreement resolves the patent litigation brought by Catalyst and SERB on Teva for submitting an abbreviated new drug application  to the FDA seeking marketing approval for a generic version ofFirdapse 10 mg tablets before applicable patents expire.Please note that Firdapse is currently approved in the United States, the EU and Japan for the symptomatic treatment ofLambert-Eaton Myasthenic Syndrome  in adults. In 2022, Catalyst received FDA approval for the label expansion of Firdapse in the United States for treating LEMS in pediatric patients . Last year, the FDA approved Catalyst’s regulatory filing to increase the maximum daily dose of Firdapse for adults and pediatric patients over 45 kg from 80 mg to 100 mg for treating LEMS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cprx-stock-rises-17-settling-145300529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0053671581.USD","BK4196","TEVA","BK4559","CSTL","BK4557","CPRX","BK4139","BK4566","BK4584","BK4585","BK4596","BK4007","HALO"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":195,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"date":"2025-05-05","symbol":"CSTL","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"defaultRemindTime":1746475200000,"name":null,"time":"Post Market","dateTimestamp":1746417600000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-04-29","current":31.761841,"percent":0.8125,"low":-703.916349,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"high":155.734424,"avg":-45.836565,"sd":148.870167,"marketCap":579494784},"quantilePoints":[{"date":"2020-05-01","current":92.390956,"twenty":-143.704042,"median":68.845748,"eighty":81.767269,"marketCap":487547076},{"date":"2020-05-08","current":102.692841,"twenty":-142.838448,"median":69.315315,"eighty":83.406552,"marketCap":541910124},{"date":"2020-05-15","current":89.505926,"twenty":-142.421108,"median":70.049766,"eighty":84.306716,"marketCap":644890198},{"date":"2020-05-22","current":90.653132,"twenty":-141.385486,"median":70.663815,"eighty":86.10245,"marketCap":653155813},{"date":"2020-05-29","current":91.848137,"twenty":-139.963439,"median":70.856459,"eighty":88.430421,"marketCap":661765829},{"date":"2020-06-05","current":90.079529,"twenty":-139.808869,"median":71.037061,"eighty":89.171324,"marketCap":649023006},{"date":"2020-06-12","current":88.478221,"twenty":-139.422443,"median":71.891914,"eighty":89.431502,"marketCap":637485584},{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-04-29","current":31.761841,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":579494784}],"updateTime":1746076395355}}}